Find in Library

In this study, a series of novel benzofuran-based 1,2,4-triazole derivatives (<b>10a–e</b>) were synthesized and evaluated for their inhibitory potential against acetylcholinesterase (AChE) and bacterial strains (<i>E. coli</i> and <i>B. subtilis</i>). Preliminary results revealed that almost all assayed compounds displayed promising efficacy against AChE, while compound <b>10d</b> was found to be a highly potent inhibitor of AChE. Similarly, these 5-bromobenzofuran-triazoles <b>10a</b>–<b>e</b> were screened against <i>B. subtilis</i> QB-928 and <i>E. coli</i> AB-274 to evaluate their antibacterial potential in comparison to the standard antibacterial drug penicillin. Compound <b>10b</b> was found to be the most active among all screened scaffolds, with an MIC value of 1.25 ± 0.60 µg/mL against <i>B. subtilis</i>, having comparable therapeutic efficacy to the standard drug penicillin (1 ± 1.50 µg/mL). Compound <b>10a</b> displayed excellent antibacterial therapeutic efficacy against the <i>E. coli</i> strain with comparable MIC of 1.80 ± 0.25 µg/mL to that of the commercial drug penicillin (2.4 ± 1.00 µg/mL). Both the benzofuran-triazole molecules <b>10a</b> and <b>10b</b> showed a larger zone of inhibition. Moreover, IFD simulation highlighted compound <b>10d</b> as a novel lead anticholinesterase scaffold conforming to block entrance, limiting the swinging gate, and disrupting the catalytic triad of AChE, and further supported its significant AChE inhibition with an IC₅₀ value of 0.55 ± 1.00 µM. Therefore, compound <b>10d</b> might be a promising candidate for further development in Alzheimer’s disease treatment, and compounds <b>10a</b> and <b>10b</b> may be lead antibacterial agents.